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Letters to the Editorconfirmed that aspirin was effective in
at least some of them. In fact, resis-
tance to aspirin in some patients might
have actually hindered the real mean
difference in bleeding and reduced
the apparent long-term benefit of
preoperative aspirin administration
among the responders.
The separate unresolved issue re-
mains the choice of platelet function
assay to use in clinical practice and
clinical trials. Let us finish by citing
the conclusions of a unique report by
Lordkipanidze and colleagues,5 who
compared in the same population 6
major different methods used to test
platelet function: ‘‘. conclusions
drawn could be highly dependent on
the test used and results from various
assays are clearly not interchangeable.
Hence, the clinical usefulness of the
different platelet function tests to de-
tect appropriately aspirin resistant
patients remains uncertain.’’
Marek A. Deja, MD, PhD
Tomasz Kargul, MD
Wojciech Domaradzki, MD
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OF THE BRONCHOSCOPIST
To the Editor:
We read with interest the report
‘‘Prospective study of endobronchial
ultrasound-guided transbronchial nee-
dle aspiration of lymph nodes versus
transbronchial lung biopsy of lung tis-
sue for diagnosis of sarcoidosis’’ by
Oki and colleagues,1 which appeared
in the June issue of the Journal.While
congratulating them for their effort in
clarifying this controversial and rele-
vant topic, we want to share some sig-
nificant concerns we had as we read
their report.
Our first concern pertains to the se-
lection of patients. To be valid, a diag-
nostic study should include patients
with diagnostic uncertainty. This is,
in part, because patients with an obvi-
ous diagnosis do not need diagnostic
tests. Although the authors included
patients with suspected stage I or II
sarcoidosis (excluding those with
biopsy proven disease), it is unclear
whether they included consecutive
patients or not. If they did not include
consecutive patients by filtering out
some individuals, it becomes crucial
to know how many and why these pa-
tients were excluded. We believe their
study could potentially have a spec-
trum bias, overestimating the diagnos-
tic power of the test by including
target-positive patients.2
Other potential problems in the
validity of the study by Oki and col-
leagues1 could also be inflating the
results. One of these is that the tests
being studied were a part of the refer-
ence standard.3 That explains why the
specificities for both tests were
100%. All patients who had epitheli-
oid cell granulomas were considered
to have sarcoidosis using the clinical,
radiologic, and pathologic criteria
used as the reference standard. Al-
though it is true a single reference
standard is not available for sarcoido-
sis and a multidisciplinary meeting is
recommended, a blind assessment
from the adjudicators of outcome
would have been preferred. It is notCardiovascular Surgery c November 20stated in their report who adjudicated
the diagnosis.
The lack of randomization regard-
ing the order of the tests also raises
a concern. This was acknowledged
by the authors in their discussion.
We can think of a few potential biases
from performing endobronchial ultra-
sonography first in every patient, and
there might be many other biases
that we have not considered. Random-
izing the order of the tests would have
been a great addition to the study
protocol and would have decreased
the chances of bias toward 1 proce-
dure or the other. In addition, before
the era of chest computed tomogra-
phy, when mainly chest radiography
was used to classify a patient as hav-
ing stage I, transbronchial biopsy
had a greater diagnostic yield.4 Cur-
rently, with high-resolution computed
tomography of the chest widely avail-
able, the yield of transbronchial
biopsy is understandably lower.5
As a final comment, we have to
discuss the applicability of the data.
Most patients included in the trial
had stage I sarcoidosis. Physicians
reading their report might leave with
the message that all patients with sus-
pected stage I sarcoidosis should
undergo biopsy. We believe that be-
cause a bronchoscopy can be done
does not mean it should be done.
The decision to establish the diagnosis
of sarcoidosis should remain in the
domain of the clinician caring for the
patient and not the bronchoscopist.
Manuel L. Ribeiro Neto, MD
Daniel A. Culver, DO
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j.jtcvs.2012.07.103Reply to the Editor:
We thank Drs Ribeiro Neto, Culver,
and Mehta for their comments regard-
ing our study comparing the diagnostic
yield of endobronchial ultrasound-
guided transbronchial needle aspira-
tion (EBUS-TBNA)and transbronchial
lung biopsy (TBLB) by showing non-
caseating granulomas for stage I and
II sarcoidosis.1 We would like to ad-
dress the issues raised by Dr Ribeiro
Neto and colleagues.
The first issue raised concerned pa-
tient selection. Our study included
consecutive patients with suspected
stage I or II sarcoidosis, regardless of
symptoms. We agree that observation
without biopsy for definitive diagnosis
in patients with suspected typical
asymptomatic stage I sarcoidosis is
reasonable; however, we think patho-
logic confirmation of a definitive or
differential diagnosis using a mini-
mally invasive and highly accurate
procedure is another valid choice. In
fact, 33 of the 62 patients enrolled in
our study were referred to our institu-
tion for EBUS-TBNA from physi-
cians at 21 hospitals at which TBLB
was available but not EBUS-TBNA.
We assume this means that many phy-
sicians empirically know the diagnos-
tic yield of TBLB is not sufficient,
especially for stage I sarcoidosis.
Moreover, many of them prefer to
have a pathologic diagnosis for the
treatment of patients with sarcoidosis,
even with asymptomatic stage IThe Journalsarcoidosis, if a highly accurate and
minimally invasive procedure is
available.
The second issue raised regarded
the method of obtaining a final diag-
nosis of sarcoidosis. As we men-
tioned, many patients enrolled in our
study were referred for diagnosis and
returned to be followed up by the re-
ferring physicians. We conducted
a follow-up survey of the patients ask-
ing the physicians regarding the clini-
coradiologic compatibility for having
sarcoidosis. For patients who were
followed up at our institution, we
carefully reviewed the medical re-
cords and radiographs. Finally, the di-
agnosis of sarcoidosis was made by
pulmonologists (M.O., H.S.). In Ja-
pan, the frequency of diseases
(eg, histoplasmosis) other than sar-
coidosis in patients with multiple
hilar-mediastinal lymphadenopathy
presenting with noncaseating epitheli-
oid cell granulomas is quite low, and
a similar result was also reported by
another Japanese group.2
The third issue raised was the limi-
tation of the nonrandomized design.
As we reported in the ‘‘Discussion’’
section, the order of these procedures
could affect the results. A large inter-
national multicenter comparative
study would elucidate more detail on
ultrasound-guided needle aspiration
procedures versus conventional
bronchoscopy.3
At a time when only conventional
procedures (eg, TBLB or mediastino-
scopy) were available for the patho-
logic diagnosis of stage I sarcoidosis,
simple observation without confirma-
tory biopsywas recommended because
of risk/benefit and cost/benefit consid-
erations.4 However, a new approach,
EBUS-TBNA, is a much less-invasive
and more accurate procedure than
these conventional procedures. We in-
vestigators must clarify the role of
this new procedure, even for asymp-
tomatic patients with stage I sarcoido-
sis, in a prospective trial approved
by an institutional review board.of Thoracic and Cardiovascular SurgerArguments advocating for confirma-
tory biopsy for asymptomatic stage I
sarcoidosis were not the aim of our
study; however, the indications should
be debated whenever a promising pro-
cedure is developed.
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SIMPLIFIED GRADING
SYSTEM WITH COMPUTED
TOMOGRAPHIC
ANGIOGRAPHY FOR BLUNT
AORTIC INJURY’’
To the Editor:
We read with interest the study on
blunt aortic injury by Lamarche and
colleagues1 and found that the classi-
fication of traumatic aortic injuries
reported in their study was very sim-
ilar to the one we published in 2009.2
Since then, our report has been cited
22 times.3 Among the studies citing
our classification system was the
2011 Clinical Practice Guidelines of
the Society for Vascular Surgery.4
We would like the authors to com-
ment on the differences betweeny c Volume 144, Number 5 1277
